<?xml version="1.0" encoding="UTF-8"?><!-- Converted from Majour with majour2a++ V1.11 --><!--Automatically converted from version 2.3 to 2.4--><!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
   <PublisherInfo>
      <PublisherName>Springer-Verlag</PublisherName>
      <PublisherLocation>Berlin/Heidelberg</PublisherLocation>
   </PublisherInfo>
   <Journal>
      <JournalInfo JournalProductType="Legacy" NumberingStyle="Unnumbered">
         <JournalID>401</JournalID>
         <JournalPrintISSN>0001-6322</JournalPrintISSN>
         <JournalElectronicISSN>1432-0533</JournalElectronicISSN>
         <JournalSPIN/>
         <JournalTitle>Acta Neuropathologica</JournalTitle>
         <JournalSubTitle/>
         <JournalAbbreviatedTitle>Acta Neuropathol</JournalAbbreviatedTitle>
<JournalSubjectGroup>
<JournalSubject Type="Primary">Legacy</JournalSubject>
</JournalSubjectGroup>
      </JournalInfo>
      <Volume>
         <VolumeInfo VolumeType="Regular">
<VolumeIDStart>101</VolumeIDStart>
<VolumeIDEnd>101</VolumeIDEnd>
<VolumeIssueCount/>
</VolumeInfo>
         <Issue IssueType="Regular">
            <IssueInfo TocLevels="0">
               <IssueIDStart>3</IssueIDStart>
               <IssueIDEnd>3</IssueIDEnd>
               <IssueHistory>
                  <OnlineDate>
                     <Year>2000</Year>
                     <Month>12</Month>
                     <Day>20</Day>
                  </OnlineDate>
                  <PrintDate>
                     <Year>2001</Year>
                     <Month>3</Month>
                     <Day/>
                  </PrintDate>
                  <CoverDate>
                     <Year>2001</Year>
                     <Month>3</Month>
                  </CoverDate>
               </IssueHistory>
               <IssueCopyright>
                  <CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
                  <CopyrightYear>2000</CopyrightYear>
               </IssueCopyright>
            </IssueInfo>
            <Article ID="Art1">
               <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
                  <ArticleID>00297</ArticleID>
                  <ArticleDOI>10.1007/s004010000297</ArticleDOI>
                  <ArticleTitle Language="En">Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain</ArticleTitle>
                  <ArticleCategory>Regular Paper</ArticleCategory>
                  <ArticleFirstPage>271</ArticleFirstPage>
                  <ArticleLastPage>276</ArticleLastPage>
                  <ArticleHistory>
                     <Received>
                        <Year>2000</Year>
                        <Month>05</Month>
                        <Day>03</Day>
                     </Received>
                  </ArticleHistory>
                  <ArticleCopyright>
                     <CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
                     <CopyrightYear>2000</CopyrightYear>
                  </ArticleCopyright>
<ArticleGrants>
<MetadataGrant Grant="OpenAccess"/>
<AbstractGrant Grant="OpenAccess"/>
<BodyPDFGrant Grant="Restricted"/>
<BodyHTMLGrant Grant="Restricted"/>
<BibliographyGrant Grant="Restricted"/>
<ESMGrant Grant="Restricted"/>
</ArticleGrants>
               </ArticleInfo>
               <ArticleHeader>
                  <AuthorGroup>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Anna-Leena</GivenName>
                           <FamilyName>Sirén</FamilyName>
                        </AuthorName>
                        <Contact>
                           <Phone>+49-551-3899627</Phone>
                           <Fax>+49-551-3899670</Fax>
                           <Email>Siren@em.mpg.de</Email>
                        </Contact>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Friederike</GivenName>
                           <FamilyName>Knerlich</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A3">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Wolfgang</GivenName>
                           <FamilyName>Poser</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A3">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Christoph H.</GivenName>
                           <FamilyName>Gleiter</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A4">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Wolfgang</GivenName>
                           <FamilyName>Brück</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Hannelore</GivenName>
                           <FamilyName>Ehrenreich</FamilyName>
                        </AuthorName>
                     </Author>
                     <Affiliation ID="A1">
                        <OrgName>Max-Planck-Institute for Experimental Medicine, Hermann-Rein Strasse 3, 37075 Göttingen, Germany</OrgName>
                        <OrgAddress>
                           <Street/>
                           <Postbox/>
                           <Postcode/>
                           <City/>
                           <State/>
                        </OrgAddress>
                     </Affiliation>
                     <Affiliation ID="A2">
                        <OrgName>Departments of Neurology and Psychiatry, Georg-August-University, Göttingen, Germany</OrgName>
                        <OrgAddress>
                           <Street/>
                           <Postbox/>
                           <Postcode/>
                           <City/>
                           <State/>
                        </OrgAddress>
                     </Affiliation>
                     <Affiliation ID="A3">
                        <OrgName>Department of Clinical Pharmacology, Georg-August-University, 37075 Göttingen, Germany</OrgName>
                        <OrgAddress>
                           <Street/>
                           <Postbox/>
                           <Postcode/>
                           <City/>
                           <State/>
                        </OrgAddress>
                     </Affiliation>
                     <Affiliation ID="A4">
                        <OrgName>Department of Neuropathology, Georg-August-University, 37075 Göttingen, Germany</OrgName>
                        <OrgAddress>
                           <Street/>
                           <Postbox/>
                           <Postcode/>
                           <City/>
                           <State/>
                        </OrgAddress>
                     </Affiliation>
                  </AuthorGroup>
                  <Abstract ID="Abs1" Language="En">
                     <Heading>Abstract.</Heading>
                     <Para> Using immunohistochemistry, expression of erythropoietin (EPO), a hypoxia-inducible neuroprotective factor, and its receptor (EPOR) were investigated in human brain tissue after ischemia/hypoxia. Autopsy brains of neuropathologically normal subjects were compared to those with ischemic infarcts or hypoxic damage. In normal brain, weak EPO/EPOR immunoreactivity was mainly neuronal. In fresh infarcts, EPO immunoreactivity appeared in vascular endothelium, EPOR in microvessels and neuronal fibers. In older infarcts reactive astrocytes exhibited EPO/EPOR immunoreactivity. Acute hypoxic brain damage was associated with vascular EPO expression, older hypoxic damage with EPO/EPOR immunoreactivity in reactive astrocytes. The pronounced up-regulation of EPO/EPOR in human ischemic/hypoxic brains underlines their role as an endogenous neuroprotective system and suggests a novel therapeutic potential in cerebrovascular disease for EPO, a clinically well-characterized and safe compound.</Para>
                  </Abstract>
                  <KeywordGroup Language="En">
                     <Keyword>Erythropoietin Erythropoietin receptor Human ischemia/hypoxia Immunoreactivity Brain</Keyword>
                  </KeywordGroup>
                  <ArticleNote Type="Misc">
                     <SimplePara>Revised, accepted: 8 August 2000</SimplePara>
                  </ArticleNote>
                  <ArticleNote Type="Misc">
                     <SimplePara>Electronic Publication</SimplePara>
                  </ArticleNote>
               </ArticleHeader>
               <BodyRef FileRef="BodyRef/PDF/401_2001_Article_297.pdf" TargetType="PDF"/>
            </Article>
         </Issue>
      </Volume>
   </Journal>
</Publisher>